Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial

Blood (2024) 144 (Supplement 1): 1032.

https://doi.org/10.1182/blood-2024-201533

Published: 2024

Journal Articles

Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG

Blood (2024) 144 (Supplement 1): 892.

https://doi.org/10.1182/blood-2024-204700

Published: 2024

Journal Articles

A Phase I/II Single Arm Study of Belantamab Mafodotin, Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Planned Interim Analysis of Safety and Efficacy. Amarc 19-02 Belacard Study

Masa Lasica, Andrew Spencer, Noemi Horvath, Wojt Janowski, Douglas Coghlan, Craig Wallington-Gates, Philip Campbell, Hock Choong Lai, Georgia McCaughan, Nicholas Weber, Anish Puliyayil, Philip Wong, Deng Yachao, Khoa Le, John Reynolds, Hang Quach

Blood (2023) 142 (Supplement 1): 2012.

https://doi.org/10.1182/blood-2023-189005

Published: 2023

Journal Articles

Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)

Blood (2023) 142 (Supplement 1): 2023.

https://doi.org/10.1182/blood-2023-185169

Published: 2023

Journal Articles

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Blood (2023) 141 (9): 1087–1091.

https://doi.org/10.1182/blood.2022018236

Published: 2023

Includes: Supplemental data

Journal Articles

A Phase 2 Single-Arm Study to Evaluate the Efficacy of Isatuximab, Pomalidomide and Low-Dose Dexamethasone, in Patients with AL Amyloidosis Not in VGPR or Better after Any Previous Therapy (IsAMYP)

Murielle Roussel, Peter Mollee, Antoine Huart, Hasib Sidiqi, Noemi Horvath, Lionel Karlin, Caroline Jacquet, Pierre Morel, Cecile Leyronnas, Sebastien Bender, Frank Bridoux, Arnaud Jaccard, Simon D. Gibbs

Blood (2022) 140 (Supplement 1): 12618–12620.

https://doi.org/10.1182/blood-2022-166337

Published: 2022

Journal Articles

Circulating RAS/RAF and DNA-Repair Gene Mutations Associates with High-Risk/Treatment Resistance in Primary Refractory Multiple Myeloma

Sridurga Mithraprabhu, John Reynolds, Rose Turner, Hang Quach, Noemi Horvath, Ian H Kerridge, Flora Yuen, Tiffany Khong, Brian G.M. Durie, Andrew Spencer

Blood (2022) 140 (Supplement 1): 9933–9934.

https://doi.org/10.1182/blood-2022-171053

Published: 2022

Journal Articles

Comparable Survival Following Allogeneic Haematopoietic Stem Cell Transplant Utilising HLA-Matched Versus Alternative Donors: A Single-Centre Retrospective, Consecutive Cohort Analysis

Alia Cibich, Rakchha Chhetri, Kirsty M. Sharplin, Naranie Shanmuganathan, David T. Yeung, Deepak Singhal, Ashanka Mahilal Beligaswatte, Noemi Horvath, Philip Selby, Leanne Purins, Judith Stevens, Peter G. Bardy, Devendra Hiwase

Blood (2022) 140 (Supplement 1): 4892–4893.

https://doi.org/10.1182/blood-2022-170726

Published: 2022

Journal Articles

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Peter Mollee, John Reynolds, Wojciech Janowski, Hang Quach, Philip Campbell, Simon D. Gibbs, Sophie Lee, James D'Rozario, Kerry Taylor, Tara Cochrane, Craig Thomas Wallington-Beddoe, Fiona Kwok, Nicholas Weber, Ian H Kerridge, Helen Weston, P. Joy Ho, Noemi Horvath, Flora Yuen, Andrew Spencer

Blood (2021) 138 (Supplement 1): 2728.

https://doi.org/10.1182/blood-2021-152500

Published: 2021

Journal Articles

Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy - Final Analysis from the Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial

Rose Turner, Hang Quach, Noemi Horvath, Ian H Kerridge, Flora Yuen, Edwin Sze-Hung Lee, Edward S. Morris, Anna Kalff, Krystal Bergin, Shreerang Sridesai, Malgorzata Gorniak, Sridurga Mithraprabhu, Tiffany Khong, John Reynolds, Andrew Spencer

Blood (2021) 138 (Supplement 1): 1663.

https://doi.org/10.1182/blood-2021-152034

Published: 2021

Journal Articles

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Peter Mollee, FRACP,MBBS,MSc,FRCPA, John Reynolds, PhD, Wojt Janowski, FRCPA,FRACP, Hang Quach, MDFRACP,FRCPA,MBBS, Philip Campbell, MBBS, Simon D. Gibbs, FRACP, FRCPA, MBBS, Sophie Lee, FRACP, FRCPA, PhD, James D'Rozario, MBBS, FRACP, FRCPA, Kerry Taylor, FRACP,FRCPA,MBBS, Tara Cochrane, MBBS,FRCPA,FRACP, Craig Thomas Wallington-Beddoe, BSc,MBBS,PhDFRACP,FRCPA, Fiona Kwok, FRACP,FRCPA,MBBS, Nicholas Weber, MBBS, Ian H. Kerridge, FRACP FRCPA MPhil BA, Helen Weston, MBBS, FRACP, FRCPA, Phoebe Joy Ho, MBBS,DPhil,FRACP,FRCPA, Noemi Horvath, MB ChB FRACP FRCPA, Flora Yuen, BBiomedSc, Andrew Spencer

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-138394

Published: 2020

Journal Articles

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

Georgia J McCaughan, MBBS, Steven Tran, BEng MBiomedE, Simon Durrant, MBBS FRCP FRCPath, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, James Morton, MBBS BSci (MD FRACP FRCPA GAICD, Noemi Horvath, MB ChB FRACP FRCPA, Andrew Spencer, Ian H. Kerridge, FRACP FRCPA MPhil BA, Jeremy An Ke Er, MBBS, Luani Barge, MChD, BSc, Adam Bryant, MBBS (Hon) PhDFRACP FRCPA, Robin J Filshie, MBChB, PhD FRACP, FRCPA, Emily Choong, BSc MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Campbell Tiley, MBBS FRACP, Anthony K Mills, MBBS FRACP FRCPA, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, John Moore, MB.BS, MD FRACP, FRCPA, Mark Hertzberg, MBBS PhDFRACP FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, P. Joy Ho, MB.BS. (Hons), D.Phil (Oxon), FRACP, FRCPA, FFSc(RCPA), M Hasib Sidiqi, MBBS, John Bashford, BSc MBBS FRACP FRCPA, David Routledge, BSc (Hons) MBChB MSc PGCert MRCP FRCPath UK RACP, Kerry Taylor, MBBS(Hons) FRACP FRCPA, Cindy H. Lee, MBBS FRACP FRCPA, Anna Kalff, MBBS (Hons) FRACP FRCPA, Wei Xia, MBBS PhD, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-138991

Published: 2020

Journal Articles

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: An Open Label Phase II Australasian Leukaemia and Lymphoma Group (ALLG) MM 018/ Asian Myeloma Network (AMN) 002 Study

Hang Quach, MD, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, Je-Jung Lee, MD PhD, Nichloas Murphy, MBBS, FRACP, FRCPA, Jae Hoon Lee, MD PhD, Kim Kihyun, MD, Jane Estell, FRACP, Noemi Horvath, MB ChB FRACP FRCPA, Richard Eek, FRACP., Bradley Augustson, MBBS FRACP FRCPA, Philip Campbell, MBBS, Rajeev Rajagopal, FRACP, Soo-Mee Bang, MDPhD, Jeffrey SY Huang, MD, PhD, Yoon Sung Soo, MD PhD, Belinda Butcher, BSci, MBiostat, PhD, Brian G.M. Durie, MD, Wee Joo Chng, MD PhD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-139174

Published: 2020

Journal Articles

A Longitudinal Evaluation of Euroflow and Combined Quantitative Immunoprecipitation (QIP) and Free Light Chain (FLC) Mass Spectometry (MS) in Functional High Risk Multiple Myeloma

Andrew Spencer, DM, Tiffany Khong, BSc, PhD, Flora Yuen, BBiomedSc, Hannah Victoria Giles, FRCPath, MRCP, Malgorzata Gorniak, BSc, Hang Quach, MBBS, FRACP, FRCPA, MD, Noemi Horvath, MBBS FRACP FRCPA, Ian H. Kerridge, FRACP,FRCPA,MPhil,BA, Edwin Sze-Hung Lee, MD FRACP, FRCP, FRCPA, FRCPath, Krystal Bergin, Shreerang Sridesai, MBBS, FRACP, FRCPA, Anna Kalff, MBBS, John Reynolds, PhD

Blood (2019) 134 (Supplement_1): 3090.

https://doi.org/10.1182/blood-2019-129760

Published: 2019

Journal Articles

Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose Dexamethasone

Anna Kalff, MBBS, Tiffany Khong, BSc, PhD, Malarmathy Ramachandran, Sam Norton, PhD, Andrew Mitchell, PhD, John Reynolds, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Noemi Horvath, MBBS FRACP FRCPA, Peter Mollee, MBBS, MMSc, FRACP, FRCPA, Nola Kennedy, Roslyn Kemp, Andrew Spencer, DM

Blood (2019) 134 (Supplement_1): 3186.

https://doi.org/10.1182/blood-2019-130154

Published: 2019

Journal Articles

Pomalidomide Alone or in Combination with Low Dose Dexamethasone As Maintenance Following Induction with Pomalidomide and Low Dose Dexamethasone in Relapsed and Refractory Myeloma (ALLG MM14)

Anna Kalff, MBBS, Nola Kennedy, John Reynolds, PhD, Hang Quach, MDFRACP,FRCPA,MBBS, Phoebe Joy Ho, MBBS, Noemi Horvath, MBBS FRACP FRCPA, Peter Mollee, FRACP, FRCPA, MBBS, MMSc, James M. D'Rozario, MBBS, FRACP, FRCPA, Kerry Taylor, FRACP,FRCPA,MBBS, Jane Estell, FRACP, Andrew Spencer, MBBS, MD FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 1986.

https://doi.org/10.1182/blood-2018-99-118231

Published: 2018

Journal Articles

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: Preliminary Outcome from the Open Label Phase II ALLGMM018/AMN003 Study

Hang Quach, MDFRACP,FRCPA,MBBS, Simon J. Harrison, MBBS,MRCP,FRCPath,FRACP,PhD, Slavisa Ninkovic, MBBS FRACP FRCPA, Jane Estell, MBBS FRACP, Noemi Horvath, MBBS FRACP FRCPA, Nick Murphy, MBBS FRACP FRCPA, Richard Eek, MBCHB, Bradley Augustson, MBBS FRACP FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Rajeev Rajagopal, Akash Kalro, MD, Robyn Hemme, Belinda Butcher, BSc(Hons) MBiostat PhDCMPP AStat, Tracey Gerber, Peter Mollee, FRACP, FRCPA, MBBS, MMSc, Brian GM Durie, MD, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP

Blood (2018) 132 (Supplement 1): 1955.

https://doi.org/10.1182/blood-2018-99-111434

Published: 2018

Journal Articles

Early Serum Free Light Chain (SFLC) Kinetics Is Highly Predictive of Renal Response in Carfilzomib/ Dexamethasone (Cfz/Dex) in Myeloma (MM) Patients with Renal Impairment (RI) — Interim Analysis of the Australian ALLG MM16 Trial

Phoebe Joy Ho, MBBS DPhil FRACP FRCPA, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Peter Mollee, FRACP, FRCPA, MBBS, MMSc, Anoop K Enjeti, MBBS, FRCPA, MD MRCP, Noemi Horvath, MBBS FRACP FRCPA, Christian E Bryant, MBBS, PhD FRACP, FRCPA, Judith Trotman, Simon Gibbs, FRACP, FRCPA, MBBS, Douglas E Joshua, BSc(Hons) MBBS DPhil FRACP FRCPA

Blood (2018) 132 (Supplement 1): 3283.

https://doi.org/10.1182/blood-2018-99-110664

Published: 2018

Journal Articles

Preliminary Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) MM17 Trial: Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone (KTd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Andrew Spencer, MBBS, FRACP, FRCPA, DM, Hang Quach, MD FRACP, FRCPA, MBBS, Noemi Horvath, MBBS FRACP FRCPA, Ian H. Kerridge, FRACP, FRCPA, MPhil, BA, Flora Yuen, BBiomedSc, Edwin Sze-Hung Lee, MD FRACP, FRCP, FRCPA, FRCPath, Edward S. Morris, BMBS, DM, Anna Kalff, MBBS, Krystal Bergin, Shreerang Sirdesai, MBBS, FRACP, FRCPA, Malgorzata Gorniak, BSc, Sridurga Mithraprabhu, PhD MSc, Tiffany Khong, BSc, PhD, John Reynolds, PhD

Blood (2018) 132 (Supplement 1): 3279.

https://doi.org/10.1182/blood-2018-99-113982

Published: 2018

Journal Articles

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor

Suzanne Lentzsch, Hang Quach, MBBS, MD, Asher A. Chanan-Khan, MD, Noemi Horvath, FRACP, Marcelo Capra, MD PhD, Roberto Ovilla, MD, Jae-Cheol Jo, MD, Ho-Jin Shin, MD, Piruntha Thiyagarajah, Himal Amin, Tineke Casneuf, PhD, Pieter Sonneveld, MDPhD, Jordan Schecter, Vania T M Hungria, MD PhD

Blood (2017) 130 (Supplement 1): 1852.

https://doi.org/10.1182/blood.V130.Suppl_1.1852.1852

Published: 2017

NARROW

Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial

Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG

A Phase I/II Single Arm Study of Belantamab Mafodotin, Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Planned Interim Analysis of Safety and Efficacy. Amarc 19-02 Belacard Study

Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

A Phase 2 Single-Arm Study to Evaluate the Efficacy of Isatuximab, Pomalidomide and Low-Dose Dexamethasone, in Patients with AL Amyloidosis Not in VGPR or Better after Any Previous Therapy (IsAMYP)

Circulating RAS/RAF and DNA-Repair Gene Mutations Associates with High-Risk/Treatment Resistance in Primary Refractory Multiple Myeloma

Comparable Survival Following Allogeneic Haematopoietic Stem Cell Transplant Utilising HLA-Matched Versus Alternative Donors: A Single-Centre Retrospective, Consecutive Cohort Analysis

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy - Final Analysis from the Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: An Open Label Phase II Australasian Leukaemia and Lymphoma Group (ALLG) MM 018/ Asian Myeloma Network (AMN) 002 Study

A Longitudinal Evaluation of Euroflow and Combined Quantitative Immunoprecipitation (QIP) and Free Light Chain (FLC) Mass Spectometry (MS) in Functional High Risk Multiple Myeloma

Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose Dexamethasone

Pomalidomide Alone or in Combination with Low Dose Dexamethasone As Maintenance Following Induction with Pomalidomide and Low Dose Dexamethasone in Relapsed and Refractory Myeloma (ALLG MM14)

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: Preliminary Outcome from the Open Label Phase II ALLGMM018/AMN003 Study

Early Serum Free Light Chain (SFLC) Kinetics Is Highly Predictive of Renal Response in Carfilzomib/ Dexamethasone (Cfz/Dex) in Myeloma (MM) Patients with Renal Impairment (RI) — Interim Analysis of the Australian ALLG MM16 Trial

Preliminary Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) MM17 Trial: Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone (KTd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only